Literature DB >> 9892012

Modulation of human mineralocorticoid receptor function by protein kinase A.

C Massaad1, N Houard, M Lombès, R Barouki.   

Abstract

The mineralocorticoid receptor (MR) acts as a ligand-dependent transcription factor modulating specific gene expression in sodium-transporting epithelia. Physiological evidence suggest a cross-talk between the cAMP- and aldosterone-signaling pathways. We provide evidence that protein kinase A (PKA), a major mediator of signal transduction pathways, modulates transcriptional activity of the human MR (hMR). Using transient transfection assays in HepG2 cells, we show that 8-bromo-cAMP, a protein kinase A activator, stimulates glucocorticoid response element (GRE)-containing promoters in a ligand-independent manner. This effect was strictly MR dependent since no activation of the reporter gene was observed in the absence of cotransfected hMR expression plasmid. Furthermore, a synergistic activation was achieved when cells were treated with both aldosterone and cAMP. This synergistic effect was also observed in the CV1 and the stable hMR-expressing M cells but was dependent on the promoter used. In particular, synergism was less pronounced in promoters containing several GREs. We show that (protein kinase-inhibiting peptide (PKI), the peptide inhibitor of PKA, prevented both cAMP and aldosterone induction, which indicates that a functional cAMP pathway is required for stimulation of transcription by aldosterone. Using MR-enriched baculovirus extracts in gel shift assays, we have shown that the binding of the MR to a GRE-containing oligonucleotide was enhanced by PKA. Increased DNA binding of hMR is likely to reflect an increase in the number of active receptors, as measured by Scatchard analysis. Using a truncated MR, we show that the N-terminal domain is required for the effect. Finally, the N-terminal truncated MR was not directly phosphorylated by PKA in vitro. We conclude that PKA acts indirectly, probably by relieving the effect of an MR repressor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892012     DOI: 10.1210/mend.13.1.0226

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  15 in total

1.  Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension.

Authors:  ShengYu Mu; Tatsuo Shimosawa; Sayoko Ogura; Hong Wang; Yuzaburo Uetake; Fumiko Kawakami-Mori; Takeshi Marumo; Yutaka Yatomi; David S Geller; Hirotoshi Tanaka; Toshiro Fujita
Journal:  Nat Med       Date:  2011-04-17       Impact factor: 53.440

2.  Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.

Authors:  Jane A Leopold; Aamir Dam; Bradley A Maron; Anne W Scribner; Ronglih Liao; Diane E Handy; Robert C Stanton; Bertram Pitt; Joseph Loscalzo
Journal:  Nat Med       Date:  2007-02-04       Impact factor: 53.440

Review 3.  Activation of mineralocorticoid receptor in salt-sensitive hypertension.

Authors:  Nobuhiro Ayuzawa; Toshiro Fujita
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

Review 4.  Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems.

Authors:  Toshiro Fujita
Journal:  J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 10.121

5.  Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway.

Authors:  Shigeru Shibata; ShengYu Mu; Hiroo Kawarazaki; Kazuhiko Muraoka; Ken-ichi Ishizawa; Shigetaka Yoshida; Wakako Kawarazaki; Maki Takeuchi; Nobuhiro Ayuzawa; Jun Miyoshi; Yoshimi Takai; Akira Ishikawa; Tatsuo Shimosawa; Katsuyuki Ando; Miki Nagase; Toshiro Fujita
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

Review 6.  Aldosterone receptor blockade in the management of heart failure.

Authors:  Emiliano A Palmieri; Bernadette Biondi; Serafino Fazio
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

Review 7.  Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.

Authors:  Miki Nagase; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2013-01-08       Impact factor: 28.314

8.  Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin.

Authors:  Xian Wu Cheng; Masafumi Kuzuya; Takeshi Sasaki; Aiko Inoue; Lina Hu; Haizhen Song; Zhe Huang; Ping Li; Kyosuke Takeshita; Akihiro Hirashiki; Kohji Sato; Guo-Ping Shi; Kenji Okumura; Toyoaki Murohara
Journal:  J Hypertens       Date:  2011-03       Impact factor: 4.844

9.  Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators.

Authors:  G Lazennec; L Canaple; D Saugy; W Wahli
Journal:  Mol Endocrinol       Date:  2000-12

10.  Osmotic stress regulates mineralocorticoid receptor expression in a novel aldosterone-sensitive cortical collecting duct cell line.

Authors:  Say Viengchareun; Peter Kamenicky; Marie Teixeira; Daniel Butlen; Geri Meduri; Nicolas Blanchard-Gutton; Christine Kurschat; Aurélie Lanel; Laetitia Martinerie; Shoshana Sztal-Mazer; Marcel Blot-Chabaud; Evelyne Ferrary; Nadia Cherradi; Marc Lombès
Journal:  Mol Endocrinol       Date:  2009-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.